Rivaroxaban plus antiplatelet therapy for coronary artery ectasia: 36-month outcomes and risk prediction from a retrospective cohort study - Poll - MDSpire

Rivaroxaban plus antiplatelet therapy for coronary artery ectasia: 36-month outcomes and risk prediction from a retrospective cohort study

  • By

  • Mengwei Feng

  • Yunjie Wu

  • Chaoqing Xie

  • Jingxian Xing

  • Deguang Wang

  • Xue Liang

  • Juan Liu

  • Hui Gao

  • Tao Geng

  • July 15, 2026

Share

Original Source(s)

Related Content